The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia
Authors:
- 1 November 2018
- journal article
- review article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 107, 1010-1019
Abstract
No abstract availableKeywords
This publication has 102 references indexed in Scilit:
- XIAP discriminates between type I and type II FAS-induced apoptosisNature, 2009
- Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomibBlood, 2009
- Cytoprotective effects of IAPs revealed by a small molecule antagonistBiochemical Journal, 2009
- Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia CellsCancer Research, 2008
- IAPs: What's in a Name?Molecular Cell, 2008
- TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid themDrug Resistance Updates, 2008
- Small-molecule XIAP antagonist restores caspase-9–mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cellsBlood, 2008
- XIAP Induces NF-κB Activation via the BIR1/TAB1 Interaction and BIR1 DimerizationMolecular Cell, 2007
- TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κBOncogene, 2003
- IAP proteins: blocking the road to death's doorNature Reviews Molecular Cell Biology, 2002